Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Clin Cancer Res. 2021 Feb 15;27(4):1069-1081. doi: 10.1158/1078-0432.CCR-20-3141. Epub 2020 Dec 1.
Although abundant myeloid cell populations in the pancreatic ductal adenocarcinoma (PDAC) microenvironment have been postulated to suppress antitumor immunity, the composition of these populations, their spatial locations, and how they relate to patient outcomes are poorly understood.
To generate spatially resolved tumor and immune cell data at single-cell resolution, we developed two quantitative multiplex immunofluorescence assays to interrogate myeloid cells (CD15, CD14, ARG1, CD33, HLA-DR) and macrophages [CD68, CD163, CD86, IFN regulatory factor 5, MRC1 (CD206)] in the PDAC tumor microenvironment. Spatial point pattern analyses were conducted to assess the degree of colocalization between tumor cells and immune cells. Multivariable-adjusted Cox proportional hazards regression was used to assess associations with patient outcomes.
In a multi-institutional cohort of 305 primary PDAC resection specimens, myeloid cells were abundant, enriched within stromal regions, highly heterogeneous across tumors, and differed by somatic genotype. High densities of CD15ARG1 immunosuppressive granulocytic cells and M2-polarized macrophages were associated with worse patient survival. Moreover, beyond cell density, closer proximity of M2-polarized macrophages to tumor cells was strongly associated with disease-free survival, revealing the clinical significance and biologic importance of immune cell localization within tumor areas.
A diverse set of myeloid cells are present within the PDAC tumor microenvironment and are distributed heterogeneously across patient tumors. Not only the densities but also the spatial locations of myeloid immune cells are associated with patient outcomes, highlighting the potential role of spatially resolved myeloid cell subtypes as quantitative biomarkers for PDAC prognosis and therapy.
尽管已有大量研究提出胰腺导管腺癌(PDAC)微环境中的髓系细胞群体可能抑制抗肿瘤免疫,但这些细胞群体的组成、它们的空间位置以及它们与患者预后的关系仍知之甚少。
为了以单细胞分辨率生成空间分辨的肿瘤和免疫细胞数据,我们开发了两种定量多重免疫荧光检测方法,以检测 PDAC 肿瘤微环境中的髓系细胞(CD15、CD14、ARG1、CD33、HLA-DR)和巨噬细胞[CD68、CD163、CD86、IFN 调节因子 5、MRC1(CD206)]。进行空间点模式分析以评估肿瘤细胞和免疫细胞之间的共定位程度。使用多变量调整的 Cox 比例风险回归来评估与患者预后的关联。
在一个包含 305 例原发性 PDAC 切除标本的多机构队列中,髓系细胞丰富,富含于基质区域,在肿瘤间高度异质,并且与体细胞基因型不同。高密度的 CD15ARG1 免疫抑制粒细胞和 M2 极化巨噬细胞与患者生存不良相关。此外,除了细胞密度外,M2 极化巨噬细胞与肿瘤细胞的接近程度与无病生存期强烈相关,揭示了免疫细胞在肿瘤区域内定位的临床意义和生物学重要性。
在 PDAC 肿瘤微环境中存在多种髓系细胞,并且在患者肿瘤间呈异质性分布。不仅髓系免疫细胞的密度,而且它们的空间位置与患者预后相关,突出了空间分辨的髓系细胞亚型作为 PDAC 预后和治疗的定量生物标志物的潜在作用。